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ABSTRACT
◥
Inhibition of the androgen receptor (AR) is the main strategy
to treat advanced prostate cancers. AR-independent treatment-
resistant prostate cancer is a major unresolved clinical problem.
Patients with prostate cancer with alterations in canonical WNT
pathway genes, which lead to b-catenin activation, are refractory
to AR-targeted therapies. Here, using clinically relevant murine
prostate cancer models, we investigated the significance of
b-catenin activation in prostate cancer progression and treatment
resistance. b-Catenin activation, independent of the cell of origin,
cooperated with Pten loss to drive AR-independent castration-
resistant prostate cancer. Prostate tumors with b-catenin activation
relied on the noncanonical WNT ligand WNT5a for sustained
growth. WNT5a repressed AR expression and maintained the
expression of c-Myc, an oncogenic effector of b-catenin activation,
by mediating nuclear localization of NFkBp65 and b-catenin.
Overall, WNT/b-catenin and AR signaling are reciprocally inhib-
ited. Therefore, inhibiting WNT/b-catenin signaling by limiting
WNT secretion in concert with AR inhibition may be useful
for treating prostate cancers with alterations in WNT pathway
genes.
Significance: Targeting of both AR and WNT/b-catenin signal-
ingmay be required to treat prostate cancers that exhibit alterations
of the WNT pathway.
Introduction
Androgen deprivation therapy (ADT) that blocks androgen recep-
tor (AR) activity is the preferred standard-of-care treatment for
patients with advanced prostate cancer (1, 2). Although ADT offers
palliative benefits, most patients eventually progress to a lethal treat-
ment-resistant stage, referred to as castration-resistant prostate cancer
(CRPC). Although reactivation of AR signaling occurs in a majority of
CRPC cases, the proportion of AR-independent prostate cancer is
increasing in the emerging CRPC (3).
Genomic alterations and therapy-induced plasticity may cause the
emergence of AR-independent CRPC. Therefore, understanding the
functional consequences of clinically observed genomic alterations in
the emergence of CRPCmay facilitate the development of appropriate
treatment strategies, especially for AR-independent tumors. One such
pathway implicated in CRPC is WNT/ß-catenin signaling (4–6). ß-
Catenin is an effector of the WNT signaling that regulates multiple
biological processes (7). The localization and stability of ß-catenin
protein are tightly regulated tomaintain epithelial homeostasis. Onco-
genic activation of ß-catenin results in a stable protein that translocates
to nucleus and functions as a transcriptional coactivator of T-cell
factor (TCF) family transcription factors leading to transcription of
target genes, such as MYC, to govern growth and metabolism (8).
WNT ligands, such as WNT5A, may govern cancer progression
through both canonical ß-catenin activation and noncanonical
signaling (9, 10).
The functional relevance of oncogenic activation of ß-catenin in
prostate cancer progression and treatment-resistance is not
clear (11–13). Here, using preclinical murine and human prostate
cancer models, we have investigated the functional impact of onco-
genic ß-catenin activation and WNT signaling in prostate cancer
progression and defined the underlining mechanisms of treatment
resistance. We show that ß-catenin activation mediates AR-
independent CRPC through WNT5a. Overall, the WNT/ß-catenin
and AR signaling pathways exhibit mutual antagonism and dual
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Human prostate cancer samples and analyses
ß-Catenin IHC was performed in prostate cancer tissue microarray
(TMA) generated using diagnostic biopsies from 33 patients with
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suitable cores for analyses. Twenty-seven patients of this TMA cohort
progressed to develop CRPC. For each stained section, the staining
intensity and percentage of cells stained were scored accounting for
membranous, cytosolic, and nuclear staining. Semiquantitative clas-
sification of staining intensity, the histoscore was calculated as pre-
viously described (14). Based on the cumulative scores, the analyzed
cores were segregated into cancers with high (above median IHC
score) or low (below median IHC score) levels of ß-catenin for further
survival analyses. For survival analyses, 27 patients that progressed to
CRPCwere selected and based on IHC histoscore divided into patients
with high and low ß-catenin. Retrospective PTEN IHC scores (14) of
ADT-treated patients (n ¼ 33) were used for correlation analyses.
Survival analysis based on low or high ß-catenin staining was carried
out in subset of ADT-treated patients with low (below median IHC
score; n ¼ 17) or high (above median IHC score; n ¼ 16) levels of
PTEN.
The genomic alterations inWNT pathway were investigated in The
Cancer Genome Atlas (TCGA) provisional dataset for prostate cancer
in patients treated with postoperative targeted therapy (15). The
clinical information on the patients that received targeted therapy
(n¼ 252) were obtained from the cBio Portal Genomic Portal (16, 17).
The patients were segregated into patients with andwithout alterations
in WNT pathway genes, which may lead to ß-catenin activation, to
perform Kaplan–Meier analyses for progression-free survival follow-
ing cancer-specific standard-of-care treatments. The patients that did
not receive any postoperative adjuvant targeted or pharmacologic
treatments were not used for analyses. Prostate adenocarcinoma
TCGA provisional (15) dataset was used to determine the significance
of WNT expression (z-score > 1.4) on progression-free survival. The
Kaplan–Meier survival curves on the extracted data were plotted using
GraphPad Prism.
Mice
The ARR2 Probasin-Cre (Pb-Cre; ref. 18), Ptenflox (19),
Ctnnb1(ex3)D/þ (20), Nkx3.1 CreERT2 (21), and RFP/þ (22) mice have
been previously described. All mice in this study were on a mixed
background and were genotyped by Transnetyx using PCR analysis of
ear notch tissue. The male littermates with only Cre expression or
without any genetic alterations were used as the wild-type (WT)
controls. Genotype-specific male mice were handled and aged until
experimental time-points or ethically approved clinical endpoints. The
expression of Cre recombinase in Nkx3-1CreERT2 mice was induced at
12 weeks of age with 160 mg/kg tamoxifen, administered by i.p.
injection 4 times over an 11-day period. The commercially available
immunocompromised CD-1 Nudes 6- to 8-week-old male mice were
used for orthograft tumor experiments as previously described (23).
For orthograft experiments, approximately 5 million murine prostate
cancer cells were injected in one of the anterior prostate lobes of male
CD-1 Nude mice. Mice were gavaged with LGK974 (1.25 mg/kg) and
its vehicle (0.5% methyl cellulose/0.5% Tween 80) once daily for
1-month post-ADT treatment. The ARRIVE guidelines were used to
design and execute experiments.
Cell lines
Human CRPC cell line, C4-2, was purchased from the ATCC, and
PC-3M cells are metastasis-derived variant of human prostate cancer
PC3 cells (24). Cell lines were mycoplasma negative and authenticated
by LGC standards. Murine prostate cancer cell lines (P1, P2, CP1, and
CP2) were generated for this study. P1 and P2 cell lines (RRID:
CVCL_VQ82; RRID:CVCL_VQ83) were derived from prostate
tumors from Ptenpc/ mice at 14 and 13 months, respectively. CP1
and CP2 cell lines (RRID:CVCL_VQ84; RRID:CVCL_VQ85) were
derived from prostate tumors from Ctnnb1pc(ex3)D/þ Ptenpcþ/ mice at
6 and 8 months, respectively. P1, P2, CP1, and CP2 cell lines were
derived using an adaptation of method published before (25).
Immunostaining, immunofluorescence, immunoblotting, and
immunoprecipitation
IHC, immunofluorescence, and immunoblottingwere performed as
previously described (23, 26). Immunoprecipitation was carried out
using Dynabeads guidelines with lysates from freshly harvested pros-
tate tumors (scale bar, 100 mm).
RNA sequencing
The library preparation and sequencing on extracted RNA was
carried out by BGI (Beijing). Expression counts were further processed
and analyzed in the R environment (version 3.2.3; GSE136080,
GSE136082, and GSE136084).
Chromatin immunoprecipitation assay
Minced frozen prostate tissue was fixed using 1% formaldehyde for
15 minutes and quenched with Glycine (125 mmol/L) at room
temperature for 5minutes. Tissues were homogenized, nuclei isolated,
and lysed.Nuclear lysateswere sonicated using the Bioruptor sonicator
on high setting 30-second on/30-second off for 25 minutes (2  10
minutes þ 1  5 minutes). Precleared chromatin samples using IgG
were used for chromatin immunoprecipitation (ChIP) assay with AR
or HA (ChIP control) antibody with protein G-agarose suspension.
After ChIP at 4C with rotation overnight, the pellet was washed and
DNA isolated and dissolved for sequencing, which was carried out at
BGI or quantitative PCR analysis. Regions of AR occupancy were
determined using USeq Version 8.6.6 and MACS Version 1.4.1
(GSE136077).
Gene set enrichment analyses and cluster analyses
Clustering analysis was performed on the log2-transformed
DESeq2-normalized counts for genes that are significantly differen-
tially expressed between a genotype and the respective control and that
are present in all of the comparisons. The significance was defined as
the pi score larger than 1.3 (p >¼ 1.3), where p¼log10(p.adj) abs
(log2FC). For clustering, hierarchical clustering from R stats package
was usedwith correlation distance and average agglomerationmethod.
Gene set enrichment analysis (GSEA) with Hallmarks gene set col-
lection from Molecular Signature Database was carried out using
GSEAPreranked algorithm with genes from RNA sequencing
(RNA-seq) differential expression analysis ranked according to the
pi score (defined above).
Murine model signatures
Genes significantly (p.adj < 0.05 and abs(log2FC) > 1) upregulated or
downregulated in prostate tumors with ß-catenin activation compared
withPtendeletion common inboth genetically engineeredmousemodel
and orthografts were used to generate ß-cateninUp andDown genesets,
respectively. Human version of genesets was generated by converting
genes frommouse ensembl IDs to human gene symbols using biomaRt
(v2.38.0) with ensembl version 92 (http://apr2018.archive.ensembl.org)
and removing duplicated gene symbols or gene symbols not mapped
(https://github.com/prepiscak/beta_catenin_article).
Seahorse bioanalyzer assay
The Seahorse XFe96Analyzer and Seahorse XFCellMito Stress Test
Kit were used to measure the oxygen consumption rates (OCR) and
b-Catenin Activation Induces AR-Independent CRPC
AACRJournals.org Cancer Res; 80(3) February 1, 2020 577
on June 9, 2020. © 2020 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from 
Published OnlineFirst November 12, 2019; DOI: 10.1158/0008-5472.CAN-19-1684 
extracellular acidification rates (ECAR) accordingly to the manufac-
turer's instructions. Total final readings were normalized to protein
content.
Transfections
All siRNA and plasmid transfections in CP and PC3M cells were
done using nucleofection (Lonza-kit V). ActiveWNT5A-V5 was a gift
from Xi He (Addgene plasmid # 43813). C4-2 cells were transfected
using nucleofection (Lonza-kit R).
Statistical analysis
GraphPad Prism 7 was used for statistical analyses. Each data-point
represents a tumor and data shown as mean  SD. For significance, 
or #, P < 0.05. For Kaplan–Meier survival analyses, the Logrank
(Mantel–Cox) test was used.
Detailed methods are available in the Supplementary Information.
Results
ß-Catenin activation cooperates with Pten loss to mediate
prostate cancer progression
Patients with prostate cancer with alterations in the canonicalWNT
pathway genes (APC, CTNNB1, RSPO2, RNF43, and ZNRF3) leading
to ß-catenin activation (4) have a significantly poorer prognosis and
survival compared with patients without any alterations (Fig. 1A and
B; Supplementary Fig. S1A). Patients with prostate cancer with
CTNNB1 (ß-catenin) alterations relapse sooner than patients without
alterations (Fig. 1C; Supplementary Fig. S1B). Although genomic
CTNNB1 alterations occur in various solid cancers, they are signifi-
cantly associatedwith poor prognosis only in prostate cancerwhere the
standard-of-care treatment is AR-targeted therapies (Fig. 1D; Sup-
plementary Fig. S1C). The reason for a difference in the observed
clinical impact is unclear but may suggest that prostate cancers with
CTNNB1 alterations are refractory to AR-targeted therapies. To
investigate the clinical relevance of ß-catenin, we studied the ß-catenin
expression in diagnostic prostate cancer biopsies by IHC (Fig. 1E).
Patients with high levels of tumoral ß-catenin who have progressed to
CRPC have significantly reduced survival compared with those with
low ß-catenin levels (Fig. 1F).
PTEN levels showed a modest but significant inverse correlation
with ß-catenin levels (Fig. 1G). Only in ADT-treated patients with low
tumoral PTEN, patients with high ß-catenin levels have significantly
poorer survival than those with low ß-catenin levels (Fig. 1H;
Supplementary Fig. S1D). Forty-three percent of primary prostate
adenocarcinomas and metastases with CTNNB1 mutations also have
PTEN loss (Supplementary Fig. S1E; ref. 6). These data may suggest
cooperation between oncogenic ß-catenin activation and PTEN loss in
prostate cancer progression.
To investigate the functional cooperation between ß-catenin
activation and Pten loss, we used a conditional Cre-loxP system
driven by Probasin-Cre expressed in both basal and luminal cells of
the murine prostatic epithelium. The Ctnnb1(ex3)D/þ-mutant mouse
model, where a single allele of Ctnnb1 gene has loxP site flanking
the exon 3, was used to achieve constitutive activation of
ß-catenin (20). The survival of mice with prostate-specific activa-
tion of ß-catenin and heterozygous or homozygous loss of Pten
(Ctnnb1pc(ex3)D/þPtenpcþ/ or Ctnnb1pc(ex3)D/þPtenpc-/, respective-
ly) was significantly shorter compared with mice with either
ß-catenin activation (Ctnnb1pc(ex3)D/þ), heterozygous (Ptenpcþ/),
or homozygous (Ptenpc/) Pten loss alone (Fig. 1I). Highlighting
the functional cooperation between Pten and ß-catenin, the survival
of mice with ß-catenin activation and Pten deletion was significantly
shorter than mice with ß-catenin activation and heterozygous loss
of Pten (Fig. 1I). Although the heterozygous, Pten loss resulted in
prostatic intraepithelial neoplasia (PIN) lesions, mice from the
other four genotypes developed prostate cancer. At 6 months, the
prostate tumor burden was significantly higher in double-mutant
Ctnnb1pc(ex3)D/þPtenpcþ/ mice than in Ctnnb1-mutant alone mice
(Supplementary Fig. S1F). Importantly, at clinical endpoint, Pten
levels were comparable between Ctnnb1-mutant tumors with either
heterozygous or homozygous Pten deletion (Supplementary
Fig. S1G–S1H). Mice with Ctnnb1-mutant prostate tumors with
complete Pten deletion had a significantly higher tumor burden
compared with mice with Ctnnb1-mutant, Pten deletion or Ctnnb1
mutant with Pten haploinsufficiency (Fig. 1J). Thus, the Ctnnb1-
activating mutation cooperates with Pten copy-number alterations
to accelerate prostate cancer progression.
ß-Catenin activation drives AR-independent metastatic CRPC
We next investigated the effects of ADT, given in the form of
castration, on murine tumors with ß-catenin activation. ADT in
Ctnnb1pc(ex3)D/þPtenpcþ/ orCtnnb1pc(ex3)D/þmice did not significant-
ly alter the survival or tumor burden (Fig. 2A–D). Similar to clinical
prostate cancer, Ctnnb1-mutant murine tumors appeared to be refrac-
tory to ADT. Based on AR and ß-catenin staining, we observed two
patterns in hormone-na€ve (HN) Ctnnb1pc(ex3)D/þPtenpcþ/ prostate
tumors, one with the glandular areas exhibiting prominent AR
staining with no nuclear ß-catenin (red highlight, Fig. 2E), contrasting
with poorly differentiated areas (lacking the glandular structures)
with prominent nuclear ß-catenin staining and little detectable
AR (black highlight, Fig. 2E). Compared with HN tumors, the
CRPC tumors in Ctnnb1pc(ex3)D/þPtenpcþ/ and Ctnnb1pc(ex3)D/þ mice
had little detectable AR (Fig. 2E; Supplementary Fig. S2A and S2B).
At clinical endpoint, more than half of the Ctnnb1pc(ex3)D/þPtenpcþ/
mice and a quarter of Ctnnb1pc(ex3)D/þ mice developed visceral metas-
tases (Supplementary Fig. S2C and S2D). Lung metastases were
also evident in more than half of the mock and ADT-treated
Ctnnb1pc(ex3)D/þPtenpcþ/ mice (Supplementary Fig. S2E). HN and
CRPC lung metastases had prominent nuclear ß-catenin, and CRPC
lung metastases were deficient for AR (Supplementary Fig. S2F).
Overall, ß-catenin activation drives AR-independentmetastatic CRPC
(mCRPC).
Prostate cancer can arise from both the AR-positive luminal and
AR-negative basal cells within the prostatic epithelium. Because
Probasin-Cre–mediated recombinations occur in both luminal and
basal cells of murine prostatic epithelium, AR-deficient mCRPC
observed in the Ctnnb1pc(ex3)D/þPtenpcþ/ mice may reflect selective
survival or expansion of AR-negative basal cells. Hence, to investigate
the functional role of Ctnnb1 mutation in mediating castration
resistance in AR-proficient cells, we applied the tamoxifen-
inducible Nkx3-1CreERT2 Cre-loxP system to induce genetic recom-
bination in the luminal prostatic epithelial cells (Supplementary
Fig. S3A; ref. 21). Using red fluorescent protein expression reporter,
we established an induction protocol to achieve 80% to 90% recom-
bination as indicated by nuclear ß-catenin staining in Ctnnb1-mutant
prostates (Supplementary Fig. S3B–S3D).
The survival of mice with prostate luminal cell–specific
activation of ß-catenin with the heterozygous or homozygous loss
of Pten (namely Ctnnb1Nkx3-1CreERT2(ex3)D/þPtenNkx3-1CreERT2þ/ or
Ctnnb1Nkx3-1CreERT2(ex3)D/þPtenNkx3-1CreERT2-/, respectively) was sig-
nificantly lower compared with mice with either ß-catenin activation
(Ctnnb1Nkx3-1CreERT2(ex3)D/þ), heterozygous (PtenNkx3-1CreERT2þ/), or
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Figure 1.
Concurrent ß-catenin activation and Pten loss in prostate cancer progression. A, Oncoprint showing canonical WNT pathway alterations in TCGA prostate cancer
dataset (n ¼ 251). B, Kaplan–Meier plot for progression-free survival in TCGA prostate cancer dataset showing cases with (n ¼ 52) and without (n ¼ 196) WNT
pathway alterations. C, Kaplan–Meier plot for progression-free survival in TCGA prostate cancer dataset showing cases with (n¼ 33) and without (n¼ 215) CTNNB1
(mutations, amplifications, and copy-number gain) alterations.D, The significance ofCTNNB1 alterations byKaplan–Meier analysis for the progression-free survival in
the indicated cancer types. E, Representative IHC images of ß-catenin in clinical prostate cancer TMA sections. Blue arrows, membrane staining without cytosolic or
nuclear staining. Red arrows, membrane, cytosolic, and nuclear staining. F, Kaplan–Meier plot for post-diagnosis survival of patients with CRPC. ß-Catenin-high
(abovemedian IHC score) patients, n¼ 13; ß-catenin-low (median and belowmedian IHC score) patients, n¼ 14.G, Scatter plot showing the correlation of ß-catenin
and PTEN IHC scores in the clinical prostate cancer samples. H, Kaplan–Meier plot for post-diagnosis survival of ADT-treated patients with low PTEN expression
(below median IHC score) and high ß-catenin (above median IHC score) patients, n ¼ 7, or low ß-catenin (median and below median IHC score) staining, n ¼ 8. I,
Kaplan–Meier plot for overall survival of mice with indicated prostate-specific genetic alterations driven by Probasin-Cre (pc). J, The prostate weight from indicated
mice. ANOVA Tukey test;  , compared with Ctnnb1pc(ex3)D/þ; #, compared with Ctnnb1pc(ex3)D/þPtenpc/.
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Figure 2.
ß-Catenin activation drives AR-independent mCRPC. A, Kaplan–Meier plot for survival of Ctnnb1pc(ex3)D/þPtenpcþ/ mice treated with ADT when prostate tumor
was palpable (150 days, dotted line). B, Prostate tumor weight at the clinical endpoint. C, Kaplan–Meier plot for survival of Ctnnb1pc(ex3)D/þ mice treated with ADT
when the prostate tumor was palpable (300 days, dotted line). D, Prostate tumor weight at the clinical endpoint. E, Representative IHC images of prostate sections
at clinical endpoint. F, Kaplan–Meier plot for survival of mice with indicated prostate-specific genetic alterations driven by tamoxifen-inducible NKx3-1Cre
(Nkx3-1CreERT2) induced at 90days (dotted-line).  , comparedwithCtnnb1Nkx3-1CreERT2(ex3)D/þ; #, comparedwithCtnnb1Nkx3-1CreERT2(ex3)D/þPtenNkx3-1CreERT2-/.G and
H, Kaplan–Meier plot for survival of Ctnnb1Nkx3-1CreERT2(ex3)D/þ (H) and Ctnnb1Nkx3-1CreERT2(ex3)D/þPtenNkx3-1CreERT2þ/ (I) mice treated at 300 days (dotted line).
I, Representative IHC images of prostate sections. J, Representative immunoblots from hormone-na€ve (HNPC) and castration-resistant (CRPC) prostate tumors.
K, AR mRNA quantification in prostate tumors (unpaired two-tailed Student t test).
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homozygous (PtenNkx3-1CreERT2-/) Pten loss alone (Fig. 2F). Although
Pten heterozygous mice developed PIN lesions at 1.5 years, the
remaining genotypes developed AR-proficient tumors with varying
latencies (Supplementary Fig. S3E). The survival and tumor burden
were similar to that observed for the Probasin Cre–driven tumors
(Fig 2F; Supplementary Fig. S3F). ADT treatment given at 300 days
did not alter the survival in Ctnnb1 or double-mutant mice (Fig. 2G
and H). Highlighting the AR dependency in luminal cell–driven
tumors, ADT significantly reduced prostate tumor burden in dou-
ble-mutant mice (Supplementary Fig. S3G–S3I). Similar to Probasin-
cre–driven tumors, at clinical endpoints, the HNprostate tumors from
double-mutant Ctnnb1Nkx3-1CreERT2(ex3)D/þPtenNkx3-1CreERT2þ/ mice
had regions with varied AR proficiency, and the CRPCs had little
detectable AR (Fig. 2I and J). Thus, independent of the cell of origin, ß-
catenin activation and Pten haploinsufficiency led to AR-independent
CRPC (Fig. 2J and K).
ß-Catenin activation antagonizes AR function
The WNT/ß-catenin and AR signaling cross-talk is unclear in
prostate cancer. Hence, we studied the effect of mutant ß-catenin on
AR function by investigating the expression of AR target genes in
Ctnnb1Nkx3-1CreERT2(ex3)D/þPtenNkx3-1CreERT2þ/ tumors (27). Com-
pared with WT prostates, the AR target gene expression was lower
in HN double-mutant tumors and was comparable between HN and
CRPC double-mutant tumors (Fig. 3A). Confirming lower AR func-
tion, theARoccupancy on the promoter regions ofAR target genes and
the total AR peaks were reduced in tumors with ß-catenin activation
(Fig. 3B–D; Supplementary Fig. S3J). In the double-mutant tumors,
truncated active ß-catenin binds to AR (Fig. 3E). Compared withWT
prostates, both Fkbp5 expression and AR binding to the promoter of
Fkbp5, an AR target gene, were significantly decreased in double-
mutant prostate tumors (Fig. 3F). Collectively, our data indicate loss of
AR function in Ctnnb1-mutant tumors with Pten haploinsufficiency.
We castrated mice 30 days after induction to investigate if activated
ß-catenin can mediate AR-independent prostate tumorigenesis by
bypassing the AR pathway (Fig. 3G). At 300 days, WT and Pten
heterozygous castrated prostates showed complete regression with no
nuclear ß-catenin (Fig. 3H). The Ctnnb1-mutant prostates from
Ctnnb1Nkx3-1CreERT2(ex3)D/þ mice also showed complete regression
with only a few prominent nuclear ß-catenin–mutant cells (black
arrows, Fig. 3H). Highlighting the dispensability of AR signaling
in Pten-null prostates, three out of four castrated prostates showed
AR-deficient PIN lesions with membranous ß-catenin staining
(Fig. 3H; Supplementary Fig. S3K). Prostates from castrated
Ctnnb1Nkx3-1CreERT2(ex3)D/þPtenNkx3-1CreERT2þ/ mice showed PIN
lesions with prominent nuclear ß-catenin (Fig. 3H; Supplementary
Fig. S3K). Emphasizing the cooperation between Ctnnb1-activating
mutation and Pten deletion in prostate tumor progression, a majority
of castrated Ctnnb1Nkx3-1CreERT2(ex3)D/þPtenNkx3-1CreERT2-/ mice
developed poorly differentiated AR-deficient tumors (Fig. 3H;
Supplementary Fig. S3K). Thus, independent of the cell of origin,
ß-catenin activation cooperates with Pten loss to drive AR pathway–
independent prostate cancer.
We next investigated the expression of ß-catenin target genes in
double-mutant prostate tumors. Compared with Pten-null prostate
tumors, the double-mutant tumors, where tumoral Pten levels were
similar to Pten-null tumors (Supplementary Fig. S1G and S1H),
showed a significant increase in expression of ß-catenin target genes
such as c-Myc, Tiam1, Axin2, and Dkk1 (Fig. 3I), with no significant
differences between ß-catenin–mutant tumors with heterozygous or
homozygous Pten loss (Supplementary Fig. S3L). Although c-Myc and
Axin2 expression was sustained in double-mutant CRPC following
ADT, expression of other ß-catenin target genes was significantly
altered compared with HN tumors (Fig. 3J). These data may suggest a
potential mutual antagonism between ß-catenin and AR pathways.
WNT signaling is enriched in Ctnnb1-mutant prostate tumor
models
To investigate the growth advantages conferred by mutant Ctnnb1
in prostate cancer, we established spheroid models from Pten-null
(Ptenpc-/) and double-mutant (Ctnnb1pc(ex3)D/þPtenpcþ/) prostate
tumors, with two cell lines from each genotype referred to as P1, P2 and
CP1, CP2 respectively (Fig. 4A–C). Overall, CP1 and CP2 formed
invasive and nonpolarized spheroids compared with the smaller and
well-polarized P1 and P2 spheroids (Fig. 4B and C). Although the P1
spheroids showed membranous ß-catenin, the CP spheroids showed
invasive spheroids with prominent nuclear ß-catenin (Fig. 4B and C).
Both P and CP spheroids were Pten deficient, and CP spheroids
showed truncated ß-catenin (Fig. 4D; Supplementary Fig. S4A). The
epithelial Pten DNA levels were significantly lower in double-mutant
(Ctnnb1pc(ex3)D/þPtenpcþ/) tumors compared with Pten heterozygous
(Ptenpcþ/) prostates, suggesting a possible further genomic loss of
Pten in double-mutant tumors (Supplementary Fig. S4B).
Compared with P cells, CP cells formed significantly bigger prostate
tumors with increased visceral metastases and shorter survival in
immunodeficient mice (Fig. 4E and F; Supplementary Fig. S4C–
S4H). The prostate tumors from P cells were cystic with membranous
ß-catenin, and CP prostate tumors were poorly differentiated with
prominent nuclear ß-catenin staining (Fig. 4F).
We next compared the transcriptomic profiles of Pten-null
(Ptenpc/) and Ctnnb1-mutant tumors (Ctnnb1pc(ex3)D/þ and
Ctnnb1pc(ex3)D/þPtenpcþ/) with WT prostates to identify genes upre-
gulated only in tumorswith ß-catenin activation (Fig. 4G). ß-Catenin–
upregulated clusters were enriched for WNT and metabolic signaling
(Supplementary Fig. S4I). Transcriptomic comparison of P and CP
tumors showed enrichment of WNT signaling in ß-catenin–
upregulated cluster enriched with Wnt5a as one of the enriched
upstream regulators (Fig. 4G; Supplementary Fig. S4J and S4K).
R-spondin2 (RPOS2) amplifications occur in about half of the prostate
cancer cases withWNT/ß-catenin pathway gene alterations (Fig. 1A).
RPOS2 potentiates WNT signaling by binding to the LGR receptors.
Although RPOS2 expression remains unaltered, the expression of
LGR5 and 6 is significantly higher in Ctnnb1-mutant prostate tumors
compared with Pten-null tumors (Fig. 4H). Suggestive of an increased
WNT signaling, the CRPC fromADT-treated Ctnnb1pc(ex3)D/þPtenpc
has increased expression of RSPO2 and LGR5 and 6 compared with
mock tumors (Fig. 4I).
Because WNT signaling was enriched, we examined the expression
of WNT ligands in the Ctnnb1-mutant models. The transcriptomic
profiles of WNT genes in prostate tumors, metastases, and CRPC
showed enrichment of a subset of WNT ligands in ß-catenin–mutant
tumors (Fig. 4J; Supplementary Fig. S4L–S4N). Among the WNTs
examined, only WNT5A enrichment significantly associated with
poor prognosis and positively correlated with CTNNB1 expression
(Fig. 4K and L; Supplementary Fig. S4O).
Wnt5a sustains the growth of Ctnnb1-mutant prostate cancer
cells
We find WNT5a, a noncanonical WNT ligand, to be clinically
relevant and enriched in prostate tumors with ß-catenin activation.
Hence, we investigated the functional relevance of Wnt5a in tumors
with ß-catenin activation. The Wnt5a expression was significantly
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Figure 3.
Mutant ß-catenin antagonizes AR function. A, Heat map showing AR target genes’ expression in WT prostates and prostate tumors. B, Heat map showing AR
enrichment on promoters of AR target genes in 10-month-old prostates and tumors (scale, fold enrichment relative to input). C, Venn diagram showing AR-bound
genes inWT prostates and Ctnnb1Nkx3-1CreERT2(ex3)D/þPtenNkx3-1CreERT2þ/ tumors. D, Total AR-bound peaks relative to input. E, Representative immunoprecipitation
immunoblots from Ctnnb1Nkx3-1CreERT2(ex3)D/þPtenNkx3-1CreERT2þ/ tumor lysates. F, Top, enrichment of AR on Fkbp5 promoter in WTNkx3.1CreERT2 and
Ctnnb1Nkx3-1CreERT2(ex3)D/þPtenNkx3-1CreERT2þ/ tumors; ANOVA Sidak's test. Bottom, Fkbp5 mRNA quantification in Ctnnb1Nkx3-1CreERT2(ex3)D/þPtenNkx3-1CreERT2þ/
tumors relative toWTNkx3.1CreERT2.G, Schematic of early castration experimentwheremicewere castrated 30 days after induction and prostate tissueswere analyzed
at day300.H,Representative IHC imagesof prostate sections fromADT-treatedmice as indicated. ADT consequences onprostates (n¼4) represented aspie charts.
I–J, mRNA quantification of ß-catenin target genes. Unpaired two-tailed Student t test for D, F, I, and J.  , P < 0.05.
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Figure 4.
Ctnnb1-mutant prostate tumor models are enriched for WNT signaling. A, Magnetic resonance imaging axial view of prostate tumors. B, Prostate tumor spheroid
cultures established from two independent Ptenpc/ (P1, P2) and Ctnnb1pc(ex3)D/þ Ptenpcþ/ (CP1, CP2) mice. C, Representative immunofluorescence cross-section
of P1 and CP2 spheroid. D, Representative immunoblot as indicated (HSC70 was loading control). E, Representative prostate tumor photos (top plot) and prostate
tumor volumes (bottom plot) generated using P1, P2, CP1, and CP2 cells. ANOVA Tukey test. Black dotted areas, prostate orthograft tumor. F, Representative IHC
images of prostate tumors. G, Transcriptomic clustering heat map ofWT prostate and tumors. H and I,mRNA quantification in prostate tumors. J, Heat map of log2-
transformed and DESeq2-normalized count matrices from RNA-seq. K, Dot plot showing the effects of WNT enrichment (z-score > 1.4) on progression-free survival
and correlation ofWNTandCTNNB1 expression in TCGAprostate cancer dataset. L,Kaplan–Meier plot for progression-free survival in TCGAprostate cancer dataset,
with high (n ¼ 28) or low (n ¼ 464) WNT5a expression. Unpaired two-tailed Student t test for H to I.  , P < 0.05.
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Figure 5.
WNT5a sustains the growthofCtnnb1-mutant prostate cancer cells.A andB,WNT5amRNAquantitation in prostate tumors (A) and orthograft (B). ANOVADunnett's
(A) and Tukey (B) tests. C, WNT5a mRNA quantitation in prostate tumors. D, mRNA quantification in CP2 cells with ß-catenin knockdown. E, Representative
immunoprecipitation immunoblots fromCtnnb1pc(ex3)D/þPtenpcþ/ tumor lysates (top) andmurine prostate cancer cell lines (bottom). F andG,mRNAquantification
in CP2 cells with TCF-4 (F) or AR (G) knockdown. H, WNT5a mRNA quantitation in WNT5a KO CP2 cells. I, Growth rate of WNT5a KO CP2 cells. J, GSEA in
prostate tumors. K, OCR in WNT5a KO cells. L andM,mRNA quantitation (L) and immunoblots (M) in WNT5a KO cells. N, GSEA of MYC targets in prostate tumors.
O–Q, Representative immunoblots (O), c-Myc mRNA quantification (P), and growth rate (Q) in PC3M cells with active WNT5a expression. Unpaired two-tailed
Student t test for C, D, F, G, and P and ANOVA Tukey test for H, I, K, L, and Q.  , P < 0.05.
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elevated in Ctnnb1-mutant prostate tumors compared with Pten-null
tumors (Fig. 5A and B). Importantly, CRPC tumors from both
Probasin- and Nkx3-1 Cre–driven double-mutant mice showed a
significant increase in Wnt5a expression when compared with HN
tumors (Fig. 5C). Wnt5a RNA scope (RNA-ISH) confirmed the
enhanced Wnt5a expression in the Ctnnb1-mutant CRPC tumor
epithelium (Supplementary Fig. S5A). Similar to ß-catenin target
genes, ß-catenin knockdown significantly decreasedWnt5a expression
in CP2 cells (Fig. 5D; Supplementary Fig. S5B). Among ß-catenin–
binding partners, TCF4 binds to ß-catenin in the Ctnnb1-mutant
models (Fig. 5E). Similar to ß-catenin knockdown, TCF4 knockdown
also significantly decreasedWnt5a expression (Fig. 5F; Supplementary
Fig. S5C). Other TCF family members, TCF7 and TCF7L1, did not
significantly alter the expression of ß-catenin target genes (Supple-
mentary Fig. S5D). Thus, activated ß-catenin may bind to TCF4 to
induce Wnt5a expression. Interestingly, AR knockdown significantly
increased Wnt5a expression in CP2 cells (Fig. 5G; Supplementary
Fig. S5E). Thus, Wnt5a expression may be induced by ß-catenin
activation and inhibited by AR.
To further investigate the functional contribution of Wnt5a, we
generated Wnt5a CRISPR knockout (KO) CP2 cells (Fig. 5H). Com-
pared with CP2 control cells, Wnt5a KO CP2 cells showed impaired
proliferation (Fig. 5I). GSEA showed increased enrichment of oxida-
tive phosphorylation inCtnnb1-mutant prostate tumors with Pten loss
compared with Pten-null tumors (Fig. 5J). The metabolic analyses of
spent-media from CP1 and CP2 Ctnnb1-mutant cells showed
increased glucose consumption, and a stable isotope tracing experi-
ment showed enriched 13C6-glucose derived metabolites in Ctnnb1-
mutant CP2 cells (Supplementary Fig. S5F–S5H). Overall, compared
with Pten-null cells, the Ctnnb1-mutant cells had elevated glucose
catabolism, whereas Wnt5a KO significantly decreased OCR and
ECAR, indicating reduced oxidative phosphorylation and glycolysis
(Fig. 5K; Supplementary Fig. S5I).
Because Wnt5a can both activate and repress Wnt/b-catenin sig-
naling (28), we next studied the expression of ß-catenin target genes in
Wnt5a KO cells (Fig. 5L). Among ß-catenin target genes, Wnt5a KO
only decreased the expression of c-Myc (Fig. 5L). Furthermore,Wnt5a
loss decreased the expression of hexokinase 2 (HK2), an Myc tran-
scriptional target, that catalyzes the rate-limiting step of glucose
metabolism (Fig. 5M). Importantly, both Ctnnb1-mutant and dou-
ble-mutant tumors (and CP orthografts) show enrichment for MYC
target genes compared with Pten-null tumors (Fig. 5N). Thus, c-Myc
may act a mediator of WNT/ß-catenin signaling in prostate can-
cer (29). Because c-Myc is a critical regulator of cellular metabo-
lism (30), by sustaining Myc expression, Wnt5a may support the
metabolism and growth ofCtnnb1-mutant prostate cancer cells. Active
WNT5a expression in humanPC3Mprostate cancer cells [as shownby
increased phosphorylation of Ca2þ/calmodulin-dependent protein
kinase II (CAMKII)—an effector of WNT5a-induced signaling]
increased c-Myc expression and growth rate compared with control
cells (Fig. 5O–Q).
Thus, Wnt5a is induced by activated ß-catenin and may play a
functional role in sustaining the growth of Ctnnb1-mutant cells.
WNT5a sustains c-Myc and inhibits AR expression
We show that ß-catenin regulates c-Myc expression in Ctnnb1-
mutant cells (Fig. 5D). Hence, we studied the cellular distribution of
ß-catenin inWnt5a KO cells. WNT5a KO decreased the nuclear levels
of ß-catenin and increased AR expression in CP2 cells (Fig. 6A andB).
Because NFkB regulates AR expression and WNT5a induces NFkB
activation (31), we investigated cellular distribution of NFkBp65
(RelA) in Wnt5a KO cells. WNT5a loss increased cytosolic and
decreased nuclear levels of NFkBp65 (RelA; Fig. 6C). Confirming
the role of ß-catenin and NFkBp65 in AR repression, ß-catenin or
NFkBp65 knockdown increased AR expression in CP2 cells (Fig. 6D).
These data suggest that by regulating nuclear localization of ß-catenin,
WNT5a sustains c-Myc expression and also induces nuclear NFkBp65
localization to inhibit AR expression. WNT5a loss also decreased the
expression of LGR5 and 6 in Ctnnb1-mutant prostate cancer cells
(Fig. 6E). Importantly, AR knockdown increased the expression of
LGR5 and 6 (mediators of WNT signaling) in WNT5a KO cells
(Fig. 6F). Together, our data suggest that ß-catenin–induced WNT5a
enhances the expression of LGR5 and 6 by repressing AR expression.
We next investigated the WNT/ß-catenin and AR mutual antag-
onism in Ctnnb1-mutant murine prostate cancer spheroid and ortho-
graft models. Although theCtnnb1-mutant spheroids were resistant to
enzalutamide and WNT5a loss decreased their growth, WNT5a loss
combined with enzalutamide further decreased spheroid formation
(Supplementary Fig. S6A). Although the survival was higher in mice
bearing WNT5a KO tumors, Wnt5a KO CP tumors at endpoint were
significantly smaller only in ADT-treated mice (Fig. 6G and H;
Supplementary Fig. S6B–S6D). Thus, the combined loss of WNT5a
and ADT inhibited the growth of Ctnnb1-mutant tumors. Next, we
investigated the impact of WNT5a on regulating AR function. Active
WNT5a expression in human C4-2 CRPC cells decreased the levels
of AR targets such as PSA and FKBP5 (Fig. 6I). As a consequence of
decreased AR function, C4-2 cells proliferated at a lower rate in the
presence of active WNT5a (Fig. 6I and J). Highlighting the AR
dependency of C4-2 CRPC cells, AR knockdown reduced the
growth of C4-2 cells (Fig. 6J). In contrast, compared with control
cells, the active WNT5a-expressing C4-2 cells showed sustained
proliferation in the absence of AR (Fig. 6J). Interestingly, AR-
deficient WNT5a-expressing C4-2 cells showed increased levels of
p-CAMKII, an effector of noncanonical WNT5a function (Fig. 6I).
Thus, AR may inhibit the noncanonical function of WNT5a, such as
Ca2þ/CAMKII signaling. Overall, AR and WNT5a exhibit mutual
antagonism.
We show that WNT5a-mediated nuclear localization of ß-catenin
and NFKBp65 sustains c-Myc and represses AR expression, respec-
tively. Our data indicate a reciprocal inhibition between WNT/ß-
catenin and AR signaling and highlight the importance of dual
targeting of both pathways in prostate cancer with ß-catenin activation
(Fig. 6K).
Dual targeting of AR and WNT signaling in Ctnnb1-mutant
prostate cancer
To confirm the mutual antagonism between AR and WNT/ß-
catenin signaling, we targeted these pathways in luminal-derived
prostate tumors bearingCtnnb1Nkx3-1CreERT(ex3)D/þPtenNkx3-1CreERTþ/
mice. We have shown that Ctnnb1-mutant tumors depend on
WNT signaling for sustained growth and hypothesize that
inhibition of WNT secretion using the PORCN inhibitor
LGK974 would diminish the growth advantage conferred by
WNT ligands including WNT5a. Therefore, we treated the
Ctnnb1
Nkx3-1CreERT(ex3)D/þ
PtenNkx3-1CreERTþ/ double-mutant mice with
ADT followed by LGK974 to inhibit WNT secretion (Supplementary
Fig. S7A). Compared with ADT alone, which resulted in AR-
independent CRPC, the combined ADT and LGK974 treatment
decreased tumor burden and proliferation, with residual tumor epi-
thelium showing high levels of nuclear ß-catenin (Fig. 7A and B;
Supplementary Fig. S7B). Thus, LGK974 treatment may restrict the
proliferation ofADT-treatedCtnnb1-mutant tumors by limitingWNT
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Figure 6.
WNT5a regulates c-Myc and AR expression. A–C, Representative immunoblots (A and C) and AR mRNA quantification (B) in WNT5a KO CP2 cells. D, AR mRNA
quantification in CP2 cells treated as indicated. E,mRNAquantification inWNT5a KOCP2 cells. F,mRNAquantification inWNT5aKOCP2 cells treatedwith siCTRL.G,
CP2 orthograft volumes of Mock- and ADT-treatedmice.H,Representative IHC images of CP2 prostate orthograft sections. I–J,Representative immunoblots (I) and
growth rates (J) in activeWNT5a-expressing C4-2 cells treated with siAR. K, Schematic showing the role ofWNT5a inmutant Ctnnb1-drivenmurine prostate cancer.
Unpaired two-tailed Student t test for E and F and ANOVA Tukey test for B, D, G, and J.  , P < 0.05.
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Figure 7.
Dual targeting of AR and WNT signaling in Ctnnb1-mutant prostate cancer. A, Prostate tumor weights from Ctnnb1Nkx3-1CreERT(ex3)D/þPtenNkx3-1CreERT2þ/ mice.
Unpaired two-tailed Student t test;  , P < 0.05. B, Representative immunostained images of prostate sections. C, GSEA of ß-catenin up and down signatures in
patients with WNT pathway alterations. D, Gene set variation analysis enrichment per patient (TCGA prostate cancer dataset) of ß-catenin up and down signatures
(two-sidedWilcoxon rank-sum test). E, Kaplan–Meier plot showing adenocarcinoma caseswithoutWNT pathway alterations with high ß-catenin up (abovemedian;
n¼ 200) and low ß-catenin up (belowmedian; n¼ 200) gene set variation analysis enrichment scores. F, Schematic showingmutual antagonism between ß-catenin
and AR signaling in prostate cancer progression.
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availability. Overall, dual targeting of AR and WNT signaling may be
required for treating prostate tumors with ß-catenin activation.
To investigate the clinical relevance of our models, we generated
ß-catenin–upregulated and –downregulated genesets (Supplementary
Fig. S7C and S7D). Consistent with the importance of WNT5a in
sustaining the growth of Ctnnb1-mutant tumors, WNT5a is a central
player associated with all top ten pathways of the ß-catenin Up geneset
(Supplementary Fig. S7E). Patients with prostate cancer with WNT
pathway genes alterations showed higher enrichment for ß-cateninUp
signature and lower enrichment of ß-catenin Down signature com-
pared with patients without alterations (Fig. 7C). Furthermore, by
performing enrichment analyses per patient, we confirm that patients
with WNT pathway genes alterations have significantly lower or
higher enrichment for ß-catenin Down or Up signature, respectively,
compared with patients without alterations (Fig. 7D). Because tumor
microenvironment can secrete WNT ligands (32), we investigated the
prognostic value of ß-catenin Up signature in the patients with
prostate cancer without WNT pathway gene alterations. Patients with
high (above median) enrichments for ß-catenin Up signature have
significantly poorer prognosis compared with those with low (below
median) enrichments (Fig. 7E).
Patients with prostate cancer with WNT pathway gene alterations
have a poor prognosis. Our murine models of mutant Ctnnb1-driven
prostate cancer are representative of prostate cancers with WNT
signaling gene alterations that may lead to ß-catenin activation.
Importantly, the AR pathway and ß-catenin activation exhibit mutual
antagonism. Prostate tumors with activated ß-catenin progress to AR-
independent CRPCs. WNT5a plays a central role in sustaining the
growth of ß-catenin–driven tumors and repressing AR expression.
Highlighting the reciprocal regulation, AR inhibitsWNT5a expression
and noncanonical functions of WNT5a. Hence, dual targeting of AR
signaling and inhibition of WNT secretion may represent a potential
therapeutic strategy to treat prostate cancers withWNT pathway gene
alterations (Fig. 7F).
Discussion
A better understanding of AR bypass pathways may facilitate new
treatment combinations to tackle AR-independent mCRPC progres-
sion (33). Patients with prostate cancer with genomic alterations in
WNT pathway (leading to ß-catenin activation) have a poor progno-
sis (4). Usingmurinemodels ofmutantCtnnb1-driven prostate cancer,
we show that ß-catenin–mutant tumors are refractory to ADT
and develop AR-independent mCRPC. Mechanistically, activated ß-
catenin–induced WNT5a governs the growth of Ctnnb1-mutant
tumors and progression to AR-independent CRPC. Our work high-
lights the antagonistic cross-talk between WNT/ß-catenin and AR
signaling and raises the possibility of dual targeting ofAR andWNT/ß-
catenin signaling in the treatment of prostate cancers with ß-catenin
activation.
The contribution of ß-catenin activation in prostate cancer pro-
gression is poorly understood. The oncogenic ß-catenin activation
cooperates with Pten loss to decrease the latency of prostate cancer
progression. Almost half of the prostate cancer cases with theCTNNB1
mutation have associated PTEN haploinsufficiency (34). Interestingly,
ß-catenin–mutant prostate tumors with Pten haploinsufficiency
exhibit further loss of Pten, mimicking Pten-null ß-catenin–mutant
tumors. Furthermore, ß-catenin inversely associates with PTEN levels
in clinical prostate cancer.
Both basal and luminal cells of prostate epithelium can harbor
oncogenic mutations and become the cell of origin in prostate
cancer (35–37). ß-Catenin activation may affect cancer progression
differently in different cells. To ascertain the role of ß-catenin acti-
vation in disease progression, we targeted the oncogenic Ctnnb1
mutation in both basal and luminal prostate epithelial cells using
both Probasin and inducible Nkx3.1 Cre. Both basal and luminal-
derived prostate tumors show cooperation of Ctnnb1 mutation with
Pten deletion, with similar cancer progression, but metastases were
evident only in mice with Probasin-cre–driven tumors.
An important question that remains in the field of prostate cancer
biology is whether AR and ß-catenin pathways cooperate or oppose
each other (38, 39). We show that mutant ß-catenin inhibits the
canonical AR functions, and the Ctnnb1-mutant prostate tumors have
pseudo-castration transcriptomic signature. Earlier work on Ctnnb1-
driven prostate cancer has implicated a confounding role for AR in
oncogenic ß-catenin–driven prostate tumorigenesis (38). We show
that under castrated conditions, Ctnnb1 mutation cooperated with
Pten loss to drive AR-independent luminal-derived prostate cancer.
Our work highlights the functional cooperation between ß-catenin
activation and Pten deletion in driving AR-independent CRPC, inde-
pendent of the cell of origin.
The noncanonical WNTs, such as WNT5a, may also govern ß-
catenin–independent pathways such as Ca2þ signaling (9). WNT5a is
one of the most enriched WNTs in mutant Ctnnb1-driven CRPC and
metastases. Specifically, expression of ß-catenin target genes such as c-
Myc required WNT5a. Mechanistically, WNT5a sustains c-Myc
expression by regulating nuclear localization of ß-catenin (even the
mutant form). Further insights into howWNT5amaymediate nuclear
localization of mutant ß-catenin may uncover regulatory components
of WNT/ß-catenin signaling beyond destruction complex. As previ-
ously shown, Axin2 induced in the absence of WNT5a may also
decrease the expression of c-Myc (40). Our work implicates a meta-
bolic role of WNT5a in Ctnnb1-mutant cells by sustaining the expres-
sion of c-Myc and HK2 (30, 41, 42). Thus, the mutant Ctnnb1-driven
glucose metabolism may support the growth of AR-independent
CRPC.
Interestingly, inCtnnb1-mutant cells,WNT5a repressedAR expres-
sion via NFkBp65. Importantly, WNT5a sustained the growth of AR
pathway–sensitive human CRPC C4-2 cells in the absence of AR.
WNT5a was sufficient to induce c-Myc expression and increase the
growth of AR-deficient PC3M human prostate cancer cells. WNT5a
expression is associated with poor progression-free survival in ADT-
treated patients with prostate cancer. Analysis of circulating tumor
cells from patients with prostate cancer highlights the prevalence of
WNT5a in resistance to AR-targeted therapy (43–45). In addition to
altering the expression ß-catenin target genes including WNT5a, AR
also inhibited WNT5a-driven noncanonical CAMKII activation.
RSPO2, commonly amplified in prostate cancer, when bound to its
receptors LGR5 or LGR6, amplifies WNT signaling. We observe that
WNT5a sustains the expression of LGR5 and LGR6 by repressing AR
expression in ß-catenin–mutant prostate tumors. Thus, by decreasing
AR expression, WNT5a may maintain the WNT/ß-catenin signaling.
In this study, we show mutual antagonism between activated
ß-catenin and AR signaling in murine prostate cancers. Tumors with
ß-catenin activation depend on WNT signaling to sustain tumor
growth, especially under ADT. The noncanonical WNT ligands such
as WNT5a can exert their effects through multiple pathways (includ-
ing ß-catenin–independent function). LGK974, a porcupine (PORCN)
inhibitor in clinical trials (46), suppresses WNT signaling by blocking
the secretion of WNTs. Combined ADT and LGK974 treatment was
effective in regressing Ctnnb1-mutant tumors. However, even in
the regressed prostates, the prostatic epithelium showed varied
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enrichment of cells with prominent nuclear ß-catenin indicative of
persistent Ctnnb1-mutant cancer cells. Hence, continuous treatment
with PORCN inhibitors may be required to restrain the growth of
ß-catenin–driven prostate tumors.
Overall, our work indicates the potential use of ß-catenin–induced
geneset signature derived frommurine models in risk stratification for
progression to CRPC in addition to the alterations in WNT pathway
genes. Based on the reciprocal regulation of WNT/ß-catenin and AR
signaling, we propose dual targeting of AR and WNT signaling in
patients with prostate cancer with genetic alterations in the WNT
pathway.
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